NVAX Novavax Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NVAX

Price (delayed)

$5.76

Market cap

$496.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.42

Enterprise value

-$301.05M

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III ...

Highlights
The revenue has soared by 73% YoY and by 7% from the previous quarter
Novavax's EPS has surged by 64% YoY and by 51% QoQ
Novavax's equity has shrunk by 80% YoY and by 12% QoQ
NVAX's gross margin is down by 46% year-on-year and by 11% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.novavax.com/
Peers: AGEN SRPT EBS BCRX

Key stats

What are the main financial stats of NVAX
Market
Shares outstanding
86.17M
Market cap
$496.36M
Enterprise value
-$301.05M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.15
Earnings
Revenue
$1.98B
EBIT
-$633.77M
EBITDA
-$604.71M
Free cash flow
-$508.92M
Per share
EPS
-$8.42
Free cash flow per share
-$6.51
Book value per share
-$8.08
Revenue per share
$25.35
TBVPS
$27.27
Balance sheet
Total assets
$2.26B
Total liabilities
$2.89B
Debt
$549.78M
Equity
-$634.08M
Working capital
-$756.55M
Liquidity
Debt to equity
-0.87
Current ratio
0.69
Quick ratio
0.58
Net debt/EBITDA
1.32
Margins
EBITDA margin
-30.5%
Gross margin
54.5%
Net margin
-33.2%
Operating margin
-32.5%
Efficiency
Return on assets
-26.4%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-32%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVAX stock price

How has the Novavax stock price performed over time
Intraday
-0.35%
1 week
-3.52%
1 month
-36.49%
1 year
-92.82%
YTD
-43.97%
QTD
-43.97%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$1.98B
Gross profit
$1.08B
Operating income
-$644.74M
Net income
-$657.94M
Gross margin
54.5%
Net margin
-33.2%
Novavax's net margin has surged by 78% YoY and by 54% QoQ
The operating margin has soared by 78% year-on-year and by 52% since the previous quarter
The revenue has soared by 73% YoY and by 7% from the previous quarter
Novavax's operating income has soared by 62% YoY and by 49% from the previous quarter

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
N/A
P/B
N/A
P/S
0.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.15
Novavax's EPS has surged by 64% YoY and by 51% QoQ
Novavax's equity has shrunk by 80% YoY and by 12% QoQ
NVAX's P/S is 99% below its 5-year quarterly average of 16.7 and 89% below its last 4 quarters average of 2.1
The revenue has soared by 73% YoY and by 7% from the previous quarter

Efficiency

How efficient is Novavax business performance
Novavax's return on sales has surged by 78% YoY and by 54% QoQ
NVAX's return on assets has surged by 60% year-on-year and by 49% since the previous quarter

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 22% lower than its total liabilities
The current ratio has declined by 35% since the previous quarter and by 23% year-on-year
NVAX's quick ratio is down by 31% since the previous quarter and by 30% year-on-year
Novavax's debt is 187% higher than its equity
Novavax's equity has shrunk by 80% YoY and by 12% QoQ
NVAX's debt to equity is up by 33% year-on-year but it is down by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.